| Preface: The successful clinical use of viral vectors for human gene therapy |
| General principles of retrovirus vector design |
| Strategies for retrovirus-based correction of severe, combined immunodeficiency (SCID) |
| Retrovirus and lentivirus vector design and methods of cell conditioning |
| Analysis of the clonal repertoire of gene corrected cells in gene therapy |
| Developing novel lentiviral vectors into clinical products |
| Lentivirus vectors in beta-thalassemia |
| Gene Therapy for Chronic Granulomatous Disease |
| Alternative splicing caused by lentiviral integration in the human genome |
| Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a-/- mice |
| Lentiviral Hematopoietic Cell Gene Therapy for X-linked Adrenoleukodystrophy |
| Retroviral replicating vectors in cancer |
| Adeno-associated virus vectorology, manufacturing and clinical applications |
| Gene Delivery To The Retina: From Mouse To Man |
| Generation of hairpin-based RNAi vectors for biological and therapeutic application |
| Recombinant adeno-associated viral vector reference standards |
| NIH oversight of human gene transfer research involving retroviral, lentiviral and adeno-associated virus vectors and the role of the NIH recombinant DNA advisory committee draft |
| Regulatory structures for gene therapy medicinal products in the European Union |
| Preface: The successful clinical use of viral vectors for human gene therapy |
| General principles of retrovirus vector design |
| Strategies for retrovirus-based correction of severe, combined immunodeficiency (SCID) |
ＥＢ
